What is VFEND and what is it used for?
VFEND contains the active substance voriconazole. VFEND is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.
It is used for the treatment of patients (adults and children aged 2 years and above) with:
- Invasive aspergillosis (a type of fungal infection due to Aspergillus sp)
- Candidaemia (another type of fungal infection due to Candida sp) in non-neutropenic patients (patients without abnormally low white blood cells count)
- Serious invasive Candida sp. infections when the fungus is resistant to fluconazole (another antifungal medicine)
- Serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two different species of fungi)
VFEND is intended for patients with worsening, possibly life-threatening, fungal infections.
VFEND is also indicated for the prevention of fungal infections in high risk bone marrow transplant recipients.
VFEND can only be obtained with a prescription and should only be taken under the supervision of a doctor.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for VFEND please follow these links:
PP-VFE-GBR-0074 / October 2021